Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Looking for participantsNCT07322237
What this trial is testing

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Who this might be right for
Cirrhotic CardiomyopathyEmpagliflozinCardiometabolic Risk Factors+1 more
Post Graduate Institute of Medical Education and Research, Chandigarh 400
Post-approval studies (Phase 4)UnknownNCT05037695
What this trial is testing

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)

Who this might be right for
Diabetes Mellitus, Type 2Coronary Artery DiseaseAcute Kidney Injury
University of Sao Paulo General Hospital 40
Early research (Phase 1)Study completedNCT03704818
What this trial is testing

Dapagliflozin Effects on Hypoglycemia

Who this might be right for
Type1 Diabetes Mellitus
University of California, San Diego 22
Post-approval studies (Phase 4)Study completedNCT04013581
What this trial is testing

Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

Who this might be right for
Type 2 Diabetes Mellitus
Yonsei University 121
Post-approval studies (Phase 4)UnknownNCT04014192
What this trial is testing

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Who this might be right for
Type 2 Diabetes Mellitus
Peking Union Medical College Hospital 40
Post-approval studies (Phase 4)Study completedNCT03089333
What this trial is testing

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Who this might be right for
HypertensionDiabetes Mellitus, Type 2Blood Pressure+4 more
University of Campinas, Brazil 16
Post-approval studies (Phase 4)Study completedNCT03007329
What this trial is testing

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Who this might be right for
Steatosis, LiverType2 Diabetes
Medical University of Vienna 34
Testing effectiveness (Phase 2)Looking for participantsNCT06182839
What this trial is testing

Canagliflozin in Advanced Renal Disease With MRI Endpoints

Who this might be right for
ESRD, CKD Stage 4, CKD Stage 5
McGill University Health Centre/Research Institute of the McGill University Health Centre 92
Not applicableActive Not RecruitingNCT06491953
What this trial is testing

SGLT2-inhibitors on PC-AKI

Who this might be right for
Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
Shenyang Northern Hospital 3,600
Large-scale testing (Phase 3)Study completedNCT04213677
What this trial is testing

Dapagliflozin Efficacy and Action in PCOS

Who this might be right for
Polycystic Ovary Syndrome
Nanfang Hospital, Southern Medical University 165
Post-approval studies (Phase 4)Study completedNCT03226457
What this trial is testing

SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Who this might be right for
Heart FailureType 2 Diabetes Mellitus
University of Dundee 23
Post-approval studies (Phase 4)Study completedNCT03959501
What this trial is testing

Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy

Who this might be right for
Type 2 DiabetesKetonemia
The University of Hong Kong 60
Post-approval studies (Phase 4)UnknownNCT03877406
What this trial is testing

Effect of Empagliflozin on Body Composition and Ketones

Who this might be right for
Diabetes MellitusFat; Intolerance, Pancreas
Seoul National University Bundang Hospital 200
Testing effectiveness (Phase 2)UnknownNCT05014594
What this trial is testing

Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT

Who this might be right for
CirrhosisAscites Hepatic
Post Graduate Institute of Medical Education and Research, Chandigarh 44
Post-approval studies (Phase 4)Study completedNCT04700839
What this trial is testing

SGLT2 Inhibitors in Patients With PCOS

Who this might be right for
Polycystic Ovary Syndrome
Shanghai 10th People's Hospital 68
Not applicableNot Yet RecruitingNCT07272057
What this trial is testing

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

Who this might be right for
Lung Cancer
Shanghai Chest Hospital 200
Post-approval studies (Phase 4)Looking for participantsNCT06249945
What this trial is testing

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Who this might be right for
Heart Failure With Preserved Ejection FractionEnd Stage Renal Disease on Dialysis
National Taiwan University Hospital 150
Post-approval studies (Phase 4)Study completedNCT05367063
What this trial is testing

Canagliflozin and Myocardial Fibrosis

Who this might be right for
Type 2 DiabetesCardiovascular Risk
Shanghai Zhongshan Hospital 45
Not applicableActive Not RecruitingNCT07127406
What this trial is testing

Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users

Who this might be right for
Diabetic KetoacidosisPostoperative Care
Kocaeli City Hospital 300
Post-approval studies (Phase 4)Study completedNCT02653209
What this trial is testing

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Who this might be right for
Type 2 Diabetes
Royal Devon and Exeter NHS Foundation Trust 525
Next Page